Shukri Abdallah Taha

Array ( [id] => 17014158 [patent_doc_number] => 11083777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Hemichannel extracellular-domain specific agents for treating ischemia-reperfusion injury [patent_app_type] => utility [patent_app_number] => 16/744326 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 15 [patent_no_of_words] => 8117 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628738 [patent_doc_number] => 20210047391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => ANTI-CGRP COMPOSITIONS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/740699 [patent_app_country] => US [patent_app_date] => 2020-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17534711 [patent_doc_number] => 20220113320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF NEURODEGENERATIVE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/422102 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17422102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17490455 [patent_doc_number] => 11279744 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => Neuropeptide Y fragment capable of releasing hematopoietic stem cells into blood and treating osteoporosis [patent_app_type] => utility [patent_app_number] => 16/733347 [patent_app_country] => US [patent_app_date] => 2020-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 10890 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16733347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16879183 [patent_doc_number] => 11029321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Method of evaluating corpus luteum function by recurrently evaluating progesterone non-serum bodily fluids on multiple days [patent_app_type] => utility [patent_app_number] => 16/732766 [patent_app_country] => US [patent_app_date] => 2020-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 13278 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 363 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17244786 [patent_doc_number] => 20210364529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => METHOD AND KIT FOR DETERMINING POSSIBILITY OF ONSET OF IGA NEPHROPATHY [patent_app_type] => utility [patent_app_number] => 17/277179 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20330830 [patent_doc_number] => 12461101 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Blood-based signatures for diagnosis and sub-typing of inflammatory bowel disease subsets [patent_app_type] => utility [patent_app_number] => 17/296941 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 29 [patent_no_of_words] => 13798 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443786 [patent_doc_number] => 20220064291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => METHODS OF USING BUTYROPHILIN ANTIBODIES FOR TREATING HIV INFECTION [patent_app_type] => utility [patent_app_number] => 17/415031 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17961363 [patent_doc_number] => 20220341944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => BIOMARKER COMBINATIONS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE [patent_app_type] => utility [patent_app_number] => 17/413772 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16483980 [patent_doc_number] => 20200377581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same [patent_app_type] => utility [patent_app_number] => 16/712494 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20453330 [patent_doc_number] => 12516382 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring PD-1/PD-L1 signaling pathway members [patent_app_type] => utility [patent_app_number] => 17/311538 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 0 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17358039 [patent_doc_number] => 20220018835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => USE OF CD26 AND CD39 AS NEW PHENOTYPIC MARKERS FOR ASSESSING MATURATION OF FOXP3+ T CELLS AND USES THEREOF FOR DIAGNOSTIC PURPOSES [patent_app_type] => utility [patent_app_number] => 17/311509 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315111 [patent_doc_number] => 11629180 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => Bifunctional angiogenesis inhibitor and use thereof [patent_app_type] => utility [patent_app_number] => 16/981652 [patent_app_country] => US [patent_app_date] => 2019-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 6953 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17415216 [patent_doc_number] => 20220050120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => BIOMARKER FOR DIAGNOSING AT-RISK MENTAL STATE [patent_app_type] => utility [patent_app_number] => 17/298513 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17298513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586493 [patent_doc_number] => 20200069781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => IMMUNOGENIC LHRH COMPOSITION AND USE THEREOF IN PIGS [patent_app_type] => utility [patent_app_number] => 16/686672 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16686672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17344988 [patent_doc_number] => 20220011319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => COMPOSITIONS AND METHODS OF PROGNOSIS AND CLASSIFICATION FOR PREECLAMPSIA [patent_app_type] => utility [patent_app_number] => 17/291858 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18128865 [patent_doc_number] => 11555064 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => Treating headache comprising administering an antibody to calcitonin gene-related peptide [patent_app_type] => utility [patent_app_number] => 16/676988 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 57618 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16676988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16197416 [patent_doc_number] => 10722552 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-07-28 [patent_title] => Treatment of autism using botulinum toxins [patent_app_type] => utility [patent_app_number] => 16/657933 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12594 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16244854 [patent_doc_number] => 10744182 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-08-18 [patent_title] => Treatment of narcotics tolerance using botulinum toxins [patent_app_type] => utility [patent_app_number] => 16/657950 [patent_app_country] => US [patent_app_date] => 2019-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12596 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17227161 [patent_doc_number] => 20210353717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION [patent_app_type] => utility [patent_app_number] => 17/285314 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285314 [rel_patent_id] =>[rel_patent_doc_number] =>)